Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects

BACKGROUND AND OBJECTIVES: Fidaxomicin treatment of Clostridium difficile infection is known to produce minimal systemic exposure, as the antibacterial (antibiotic) remains primarily in the gut. In this randomized, double-blind, placebo-controlled study, the safety, tolerability, and pharmacokinetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Oshima, Hiroyuki, Yamazaki, Takao, Benner, Lauren, Miki, Takashi, Michon, Ingrid, Wojtkowski, Tomasz, Kaibara, Atsunori, Mujais, Salim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449367/
https://www.ncbi.nlm.nih.gov/pubmed/25972286
http://dx.doi.org/10.1007/s40261-015-0291-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449367/
https://www.ncbi.nlm.nih.gov/pubmed/25972286
http://dx.doi.org/10.1007/s40261-015-0291-9

Ejemplares similares